© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Heather H. Cheng, MD, PhD | Authors
Articles
Targeting the Androgen Receptor Signaling Axis to Reduce Testosterone Levels in Prostate Cancer: How Low Should We Go?
August 15, 2014
It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.